Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun;12(6):990-998.
doi: 10.1016/j.jchf.2024.04.010.

Screening for Unrecognized HFpEF in Atrial Fibrillation and for Unrecognized Atrial Fibrillation in HFpEF

Yogesh N V Reddy  1 , Peter Noseworthy  2 , Barry A Borlaug  2 , Nancy M Albert  3
Affiliations
Free article
Review

Screening for Unrecognized HFpEF in Atrial Fibrillation and for Unrecognized Atrial Fibrillation in HFpEF

Yogesh N V Reddy et al. JACC Heart Fail. 2024 Jun.
Free article

Abstract

Because of the bidirectional relationship between atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF), individuals with either condition require consideration of screening for the other. In this review, we summarize current evidence and rationale for screening for occult HFpEF in adults with clinical AF; and occult AF in patients with clinically recognized HFpEF. Assessment of pretest probability for occult HFpEF in symptomatic AF patients may help guide additional testing such as exercise right heart catheterization to diagnose HFpEF and guide HFpEF-specific therapies. In patients with HFpEF, AF screening will identify cases of occult AF where anticoagulation may decrease stroke risk, and correlation of previously unknown AF episodes with paroxysmal symptoms may prompt consideration for rhythm control. Therefore, screening may help clinicians understand the etiology of the often-overlapping symptoms, and it may help guide treatments to slow progression of both conditions and their complications.

Keywords: atrial fibrillation; heart failure with preserved ejection fraction; screening.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Reddy has received grants from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) Award Number K23HL164901, Sleep Number, Bayer, United Pharmaceuticals, and the Earl Wood Career Development Award from Mayo Clinic. Dr Borlaug has received grants from the National Institutes of Health (R01 HL128526, R01 HL162828, and U01 HL160226) and the United States Department of Defense (W81XWH2210245), AstraZeneca, Axon, GlaxoSmithKline, Medtronic, Mesoblast, Novo Nordisk, Rivus, and Tenax Therapeutics. Dr Borlaug has received consulting fees from Actelion, Amgen, Aria, Axon Therapies, BD, Boehringer Ingelheim, Cytokinetics, Edwards Lifesciences, Eli Lilly, Imbria, Janssen, Merck, Novo Nordisk, NGM, NXT, and VADovations; and is named inventor (US Patent number 10,307,179) for the tools and approach for a minimally invasive pericardial modification procedure to treat heart failure. Dr Albert has received grants form AstraZeneca and Roche; and has received consulting fees from American Regent, AstraZeneca, Boehringer Ingelheim, Cytokinetics, Daiichi Sankyo, Eli Lilly, Lexicon, and Merck. Dr Noseworthy has reported that he has no relationships relevant to the contents of this paper to disclose.

Similar articles

See all similar articles

Cited by

MeSH terms

LinkOut - more resources